BCEL Atreca Inc.

15.5
-0.04  -0%
Previous Close 15.54
Open 15.85
52 Week Low
52 Week High
Market Cap $568,954,021
Shares 36,706,711
Float 22,009,206
Enterprise Value $311,175,288
Volume 193,682
Av. Daily Volume 191,809
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATRC-101
Solid tumors
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the…

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the potential for ATRC-101 as a combination therapy with checkpoint inhibitors targeting the PD-1/PD-L1 axis. We expect to initiate combination studies with a checkpoint inhibitor as well as with chemotherapy, and to commence monotherapy expansion cohorts, in 2021."

    Recent Developments and Highlights

    • Screening in the Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing, and patients are currently being enrolled in the third dose cohort. To date, seven clinical trial sites have been activated, including two additional sites in the third quarter of 2020, and Atreca expects to announce initial summary data from the study in the first half of 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.



    • Atreca presented two posters describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020). The presentations provide insight into the cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101 as well as the potent single-agent activity of ATRC-101 in syngeneic mouse tumor models. Both posters are currently available on Atreca's website.

    Third Quarter 2020 Financial Results

    • As of September 30, 2020, cash, cash equivalents and investments totaled $259.5 million.



    • Research and development expenses for the three months ended September 30, 2020 were $16.8 million, including non-cash share-based compensation expense of $1.6 million.



    • General and administrative expenses for the three months ended September 30, 2020 were $6.6 million, including non-cash share-based compensation expense of $1.9 million.



    • Atreca reported a net loss of $22.9 million, or basic and diluted net loss per share attributable to common stockholders of $0.66, for the three months ended September 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

     
     
    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)
         
      September 30,December 31, 
       2020   2019 
         
    ASSETS    
         
    Current Assets
    Cash and cash equivalents $133,072  $157,954 
    Investments  126,192   14,663 
    Prepaid expenses and other current assets  4,898   3,502 
    Total current assets  264,162   176,119 
    Property and equipment, net  7,783   5,771 
    Long-term investments  205   10,799 
    Deposits and other  3,043   3,026 
    Total assets $275,193  $195,715 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY
         
    Current Liabilities
    Accounts payable $2,524  $2,133 
    Accrued expenses  5,309   5,395 
    Other current liabilities  1,442   419 
    Total current liabilities  9,275   7,947 
    Capital lease obligations, net of current portion  17   53 
    Deferred rent  4,621   763 
    Total liabilities  13,913   8,763 
         
         
    Stockholders' equity
    Common stock  4   3 
    Additional paid-in capital  488,593   351,039 
    Accumulated other comprehensive income  117   16 
    Accumulated deficit  (227,434)  (164,106)
    Total stockholders' equity  261,280   186,952 
    Total liabilities and stockholders' equity $275,193  $195,715 
         





     
    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
           (unaudited)
              
       Three Months Ended Nine Months Ended
       September 30, September 30,
        2020   2019   2020   2019 
    Expenses        
     Research and development $16,808  $12,812  $45,198  $40,447 
     General and administrative  6,614   4,864   20,195   10,919 
     Total expenses  23,422   17,676   65,393   51,366 
    Interest and other income (expense)        
     Other income  353   619   987   1,805 
     Interest income  142   1,189   1,082   2,328 
     Interest expense  (1)  (1)  (3)  (5)
     Preferred stock warrant liability revaluation           (123)
     Foreign exchange loss     (1)     (1)
     Loss on disposal of property and equipment           (7)
    Loss before Income tax expense  (22,928)  (15,870)  (63,327)  (47,369)
    Income tax expense  (1)  (1)  (1)  (2)
    Net loss $(22,929) $(15,871) $(63,328) $(47,371)
    Net loss per share, basic and diluted $(0.66) $(0.57) $(2.09) $(4.03)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  34,723,888   27,949,682   30,313,047   11,747,825 
              



    Contacts


    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251, ext. 251

    Media:

    Sheryl Seapy, 213-262-9390

     

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 2020 Next IO Summit
    Friday, November 13, 2020
    Fireside Chat time: 2:45 p.m. EST

    Stifel 2020 Virtual Healthcare Conference
    Wednesday, November 18, 2020
    Fireside Chat time: 4:40 p.m. EST

    Evercore ISI 3rd Annual HealthCONx
    Wednesday, December 2, 2020
    Panel Discussion time: 10:30 a.m. EST
    Title: "Finders Keepers: Identifying New Cancer Targets"

    Live audio webcasts of the…

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 2020 Next IO Summit

    Friday, November 13, 2020

    Fireside Chat time: 2:45 p.m. EST

    Stifel 2020 Virtual Healthcare Conference

    Wednesday, November 18, 2020

    Fireside Chat time: 4:40 p.m. EST

    Evercore ISI 3rd Annual HealthCONx

    Wednesday, December 2, 2020

    Panel Discussion time: 10:30 a.m. EST

    Title: "Finders Keepers: Identifying New Cancer Targets"

    Live audio webcasts of the Cowen and Stifel presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay of each webcast will be available on the company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390



    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two upcoming poster presentations describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. ATRC-101 is a novel, first-in-class therapeutic candidate derived from a human antibody discovered by Atreca, which targets a tumor-associated ribonucleoprotein (RNP) complex and is currently in Phase 1b clinical development.

    Details are…

    SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two upcoming poster presentations describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. ATRC-101 is a novel, first-in-class therapeutic candidate derived from a human antibody discovered by Atreca, which targets a tumor-associated ribonucleoprotein (RNP) complex and is currently in Phase 1b clinical development.

    Details are as follows:

    Title: Cooperation Between Checkpoint Inhibitors Targeting the PD-1/PD-L1 Axis and ATRC-101, a Novel Clinical-Stage Candidate for the Treatment of Solid Tissue Malignancies

    Authors: Amy Manning-Bog, Ph.D., et al.

    Poster/Abstract Number: 469

    Title: ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action

    Authors: Alexander Scholz, Ph.D., et al.

    Poster/Abstract Number: 689

    Abstracts and posters can be accessed on the SITC website once the conference begins on Monday, November 9th at 8:00 a.m. EDT. The posters will also be made available on the Atreca website.

    About ATRC-101

    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that, in preclinical models, engages the innate immune system to cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a tumor-specific ribonucleoprotein (RNP) complex. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients. Atreca initiated a Phase 1b first-in-human study of ATRC-101 in patients with select solid tumor cancers in early 2020. Clinical trials to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with chemotherapy are planned for 2021, as well as in monotherapy dose expansion cohorts in the ongoing Phase 1b trial.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 949-903-4750



    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020
    Wednesday, September 16, 2020
    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020
    Thursday, September 17, 2020
    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at…

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020

    Wednesday, September 16, 2020

    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020

    Thursday, September 17, 2020

    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of each webcast will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390



    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  5. SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase…

    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase 1b first-in-human study evaluating ATRC-101 continues to enroll patients and now has five trial sites active. In addition, our recently announced strategic collaboration with Xencor to develop bispecific T cell-engaging antibodies underscores the value of novel targets in oncology and the ability of our technology platform to attract weaponization partners. We believe these milestones, coupled with our strengthened financial position from the completion an equity financing in July, position us well for continued progress in the second half of 2020."

    Recent Developments and Highlights

    • A Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing. Screening continues in the study and patients are currently being enrolled in the second dose cohort. To date, five clinical trial sites have been activated. Atreca expects to announce initial safety data from the study in late 2020 or early 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.

       
    • Atreca hosted a webinar in June to present new preclinical data regarding the novel target and mechanism of action of ATRC-101, demonstrating both innate and adaptive immune system activation and target induction via chemotherapy.

       
    • Atreca entered into a strategic collaboration and license agreement with Xencor, Inc. to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology. Under a three-year discovery program, Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Atreca and Xencor may also pursue up to two programs independently, with a mid-to high-single digit percent royalty payable on net sales.

       
    • Atreca strengthened its financial position with the completion of a public equity offering in July 2020, resulting in net proceeds of approximately $117.5 million.

       
    • Atreca appointed Ms. Kristine M. Ball to the Company's board of directors. Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning.

       
    • Atreca continues to collaborate with BeiGene, and IGM Biosciences on a potential novel antibody treatment for COVID-19.

    Second Quarter 2020 Financial Results

    • As of June 30, 2020, cash, cash equivalents and investments totaled $148.8 million. In addition, Atreca completed a public equity offering in July 2020 resulting in net proceeds of approximately $117.5 million, and after deducting the underwriting discounts and commissions and estimated offering expenses.

       
    • Research and development expenses for the three months ended June 30, 2020 were $14.2 million, including non-cash share-based compensation expense of $1.8 million.

       
    • General and administrative expenses for the three months ended June 30, 2020 were $6.5 million, including non-cash share-based compensation expense of $1.6 million.

       
    • Atreca reported a net loss of $20.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.71, for the three months ended June 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "continue," "expects," "planned," "may," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Atreca, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share data)

          
     June 30,  December 31,  
     2020  2019 
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents$  100,430  $  157,954 
    Investments  43,088    14,663 
    Prepaid expenses and other current assets  5,112    3,502 
    Total current assets  148,630    176,119 
    Property and equipment, net  7,666    5,771 
    Long-term investments  5,311    10,799 
    Deposits and other  2,934    3,026 
    Total assets$  164,541  $  195,715 
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $  1,060  $  2,133 
    Accrued expenses  4,434    5,395 
    Other current liabilities  1,859    419 
    Total current liabilities  7,353    7,947 
    Capital lease obligations, net of current portion  29    53 
    Deferred rent  2,887    763 
    Other non-current liabilities  157    -  
    Total liabilities  10,426    8,763 
          
          
    Stockholders' equity
    Common stock  3    3 
    Additional paid-in capital  358,401    351,039 
    Accumulated other comprehensive income  216    16 
    Accumulated deficit  (204,505)   (164,106)
    Total stockholders' equity   154,115    186,952 
    Total liabilities and stockholders' equity $  164,541  $  195,715 
          



    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (unaudited)

    ($ amounts in 000's, except per share amounts)           
                 
      Three Months Ended

      Six Months Ended

     
      June 30,

      June 30,

     
      2020  2019  2020  2019 
    Expenses           
     Research and development$  14,180  $  15,922  $  28,390  $  27,635 
     General and administrative  6,458    3,537    13,581    6,055 
     Total expenses  20,638    19,459    41,971    33,690 
    Interest and other income (expense)           
     Other income  403    1,021    634    1,186 
     Interest income  255    594    940    1,139 
     Interest expense  (1)   (2)   (2)   (4)
     Preferred stock warrant liability revaluation  —     (73)   —     (123)
     Loss on disposal of property and equipment  —     (2)   —     (7)
    Loss before Income tax expense  (19,981)   (17,921)   (40,399)   (31,499)
    Income tax expense  -     -     -     (1) 
    Net loss$  (19,981) $  (17,921) $  (40,399) $  (31,500)
    Net loss per share, basic and diluted$  (0.71) $  (3.67) $  (1.44) $  (8.97)
    Weighted-average shares used in computing            
    net loss per share, basic and diluted  28,144,714    4,888,987    28,082,930    3,512,606 
                 



    Contacts



    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Primary Logo

    View Full Article Hide Full Article
View All Atreca Inc. News